Bavdegalutamide
A nonsteroidal antiandrogen for prostate cancer treatment
| Bavdegalutamide | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Bavdegalutamide is a nonsteroidal antiandrogen (NSAA) that is under investigation for the treatment of prostate cancer. It is designed to inhibit the action of androgens, which are male hormones that can promote the growth of cancer cells in the prostate.
Mechanism of Action[edit | edit source]
Bavdegalutamide functions by binding to the androgen receptor (AR) and inhibiting its activity. The androgen receptor is a type of nuclear receptor that is activated by binding to androgens, such as testosterone and dihydrotestosterone (DHT). By blocking this receptor, bavdegalutamide prevents androgens from stimulating the growth of prostate cancer cells.
Development and Clinical Trials[edit | edit source]
Bavdegalutamide is currently in the clinical trial phase of development. It is being studied for its efficacy and safety in patients with advanced prostate cancer, particularly those who have become resistant to other forms of hormone therapy. The drug is being evaluated in various phases of clinical trials to determine its optimal dosing, effectiveness, and potential side effects.
Pharmacokinetics[edit | edit source]
The pharmacokinetics of bavdegalutamide involve its absorption, distribution, metabolism, and excretion in the body. As a nonsteroidal compound, it is designed to have a favorable pharmacokinetic profile, allowing for effective inhibition of the androgen receptor with minimal side effects. The specific pharmacokinetic parameters are being studied in ongoing clinical trials.
Potential Side Effects[edit | edit source]
As with other nonsteroidal antiandrogens, bavdegalutamide may have side effects, although the specific profile is still under investigation. Common side effects of NSAAs can include fatigue, hot flashes, and gastrointestinal disturbances. The safety profile of bavdegalutamide will be better understood as clinical trials progress.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
